False
1-8 of 8 results for “红塔红土信息产业精选股票发起式c 基金持仓”
By James Strachan
March 19, 2019
The striking combination of remarkable, long-lasting, clinical effectiveness and a hefty price tag presents a real challenge to health technology assessors considering cell and gene therapies...
0 min read
By Maryam Mahdi
October 28, 2019
Sitting Down With… Charles Gore, Executive Director, Medicines Patent Pool (MPP), Geneva, Switzerland.
0 min read
By Maryam Mahdi
October 15, 2019
When it comes to human health, we know that genetics is a key factor, as is the environment...
0 min read
By Maryam Mahdi
October 1, 2019
Venturing into the unknown to harness the microbiome for human health
0 min read
By Maryam Mahdi
December 4, 2019
A novel protein-engineered hydrogel offers a less toxic sustained release alternative to synthetic platforms
0 min read
By Maryam Mahdi
October 21, 2019
Drugs used to treat retinal disorders appear to pass into breast milk, posing a potential risk to the normal development of nursing infants
0 min read
By Bill Milligan
April 2, 2019
As long as payers recognize the value of a curative treatment and manufacturers are flexible with payment plans, patients will have access to cell and gene therapies.
0 min read
By Aaron Schieving
March 18, 2019
If you or your supplier are working with animal-derived components then you run the risk of exposing patients to dangerous contaminations.
0 min read
False